Related Experiment Videos
Long-term pharmacotherapy for obesity.
1Division of Geriatrics and Nutritional Sciences, Center for Human Nutrition, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8031, St. Louis, MO 63110, USA. sklein@im.wustl.edu
Obesity Research
|February 3, 2005
Summary
For long-term weight management, obese patients may need medication alongside lifestyle changes to prevent weight regain. Sibutramine and orlistat are US-approved options, effective even with comorbidities like hypertension or diabetes.
Area of Science:
- Obesity treatment and pharmacotherapy
- Metabolic and endocrine disorders
Background:
- Lifestyle modifications alone are often insufficient for significant, sustained weight loss in obese individuals.
- Long-term obesity management is crucial to prevent weight regain.
- Pharmacological interventions are increasingly considered for managing obesity.
Purpose of the Study:
- To review the role of pharmacotherapy in long-term obesity management.
- To highlight available long-term anti-obesity medications in the United States.
- To emphasize the importance of combination therapy for optimal outcomes.
Main Methods:
- Review of clinical trial data on available long-term obesity medications.
- Analysis of drug efficacy in inducing and maintaining weight loss.
- Consideration of drug use in patients with comorbid conditions.
Main Results:
- Sibutramine and orlistat are the primary US-approved drugs for long-term obesity treatment.
- Both medications have demonstrated efficacy in clinical trials for weight loss and maintenance.
- These drugs are effective in patients with coexisting conditions like hypertension and type 2 diabetes.
Conclusions:
- Pharmacotherapy, including sibutramine and orlistat, is a viable option for long-term obesity management.
- Sustained weight loss requires ongoing treatment to prevent regain.
- Optimal results are achieved when drug therapy is integrated with behavior modification and structured meal plans.